Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (7): 690-697.doi: 10.19982/j.issn.1000-6621.20220023
• Original Articles • Previous Articles Next Articles
ZHONG Qian-hong1, MA Xiao-hui1, ZHONG Yong-hui1, ZHAO Zhi-meng1, ZHANG Xi-lin1(), XU Bang2, LUO Jie-ying3, ZHONG Li-ping4, DAI Lei5
Received:
2022-02-09
Online:
2022-07-10
Published:
2022-07-06
Contact:
ZHANG Xi-lin
E-mail:zhangxlsn@163.com
Supported by:
ZHONG Qian-hong, MA Xiao-hui, ZHONG Yong-hui, ZHAO Zhi-meng, ZHANG Xi-lin, XU Bang, LUO Jie-ying, ZHONG Li-ping, DAI Lei. Analysis of recurrence rate of pulmonary tuberculosis patients in Foshan and the influencing factors from 2014 to 2018[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 690-697. doi: 10.19982/j.issn.1000-6621.20220023
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220023
变量 | 复发 | 未复发 | HR(95%CI)值 | P值 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
例数 | 构成比(%) | 例数 | 构成比(%) | ||||||||||||
性别 | 0.004 | ||||||||||||||
男 | 129 | 1.2 | 10457 | 99.8 | 1.00 | ||||||||||
女 | 32 | 0.7 | 4590 | 99.3 | 0.57(0.39~0.84) | ||||||||||
年龄(岁) | 0.007 | ||||||||||||||
≤50 | 96 | 0.9 | 10405 | 99.1 | 1.00 | ||||||||||
>50 | 65 | 1.4 | 4642 | 98.6 | 1.54(1.12~2.11) | ||||||||||
少数民族 | 0.506 | ||||||||||||||
否 | 156 | 1.1 | 14443 | 98.9 | 1.00 | ||||||||||
是 | 5 | 0.8 | 604 | 99.2 | 0.74(0.30~1.80) | ||||||||||
本地户籍 | 0.010 | ||||||||||||||
否 | 71 | 0.9 | 8148 | 99.1 | 1.00 | ||||||||||
是 | 90 | 1.3 | 6899 | 98.7 | 1.50(1.10~2.05) | ||||||||||
患者来源 | |||||||||||||||
健康检查 | 4 | 0.4 | 914 | 99.6 | 1.00 | ||||||||||
接触者检查 | 0 | 0.0 | 82 | 100.0 | - | 0.994 | |||||||||
因症就诊 | 20 | 1.1 | 1841 | 98.9 | 2.44(0.84~7.15) | 0.103 | |||||||||
转诊 | 106 | 1.1 | 9527 | 98.9 | 2.45(0.90~6.64) | 0.079 | |||||||||
追踪 | 31 | 1.2 | 2650 | 98.8 | 2.56(0.91~7.22) | 0.076 | |||||||||
其他 | 0 | 0.0 | 33 | 100.0 | - | 0.996 | |||||||||
就诊间隔大于14d | 0.001 | ||||||||||||||
否 | 54 | 1.6 | 3311 | 98.4 | 1.00 | ||||||||||
是 | 107 | 0.9 | 11736 | 99.1 | 0.59(0.42~0.81) | ||||||||||
空洞 | <0.001 | ||||||||||||||
否 | 94 | 0.8 | 10972 | 99.2 | 1.00 | ||||||||||
是 | 67 | 1.6 | 4075 | 98.4 | 1.91(1.40~2.61) | ||||||||||
变量 | 复发 | 未复发 | HR(95%CI)值 | P值 | |||||||||||
例数 | 构成比(%) | 例数 | 构成比(%) | ||||||||||||
诊断时痰检结果 | <0.001 | ||||||||||||||
涂阴 | 67 | 0.6 | 10311 | 99.4 | 1.00 | ||||||||||
涂阳 | 94 | 2.0 | 4689 | 98.0 | 3.07(2.24~4.20) | ||||||||||
治疗2个月末痰检结果 | <0.001 | ||||||||||||||
涂阴 | 130 | 0.9 | 14164 | 99.1 | 1.00 | ||||||||||
涂阳 | 12 | 3.3 | 349 | 96.7 | 3.77(2.09~6.81) | ||||||||||
培养结果 | 0.005 | ||||||||||||||
培阴 | 3 | 0.2 | 1559 | 99.8 | 1.00 | ||||||||||
培阳 | 17 | 1.1 | 1486 | 98.9 | 5.92(1.73~20.2) | ||||||||||
合并其他结核 | 0.144 | ||||||||||||||
否 | 151 | 1.1 | 13515 | 98.9 | 1.00 | ||||||||||
是 | 10 | 0.6 | 1532 | 99.4 | 0.62(0.33~1.18) | ||||||||||
合并症 | 0.006 | ||||||||||||||
否 | 142 | 1.0 | 14025 | 99.0 | 1.00 | ||||||||||
是 | 19 | 1.8 | 1022 | 98.2 | 1.95(1.21~3.15) | ||||||||||
糖尿病 | <0.001 | ||||||||||||||
否 | 145 | 1.0 | 14410 | 99.0 | 1.00 | ||||||||||
是 | 16 | 2.5 | 637 | 97.5 | 2.57(1.53~4.30) | ||||||||||
患者诊断分型 | |||||||||||||||
原发性肺结核 | 0 | 0.0 | 1 | 100.0 | - | - | |||||||||
血行播散性肺结核 | 0 | 0.0 | 18 | 100.0 | - | - | |||||||||
继发性肺结核 | 161 | 1.1 | 15028 | 98.9 | - | - | |||||||||
重症 | 0.184 | ||||||||||||||
否 | 136 | 1.0 | 13226 | 99.0 | 1.00 | ||||||||||
是 | 25 | 1.4 | 1821 | 98.6 | 1.34(0.87~2.05) | ||||||||||
治疗管理方式 | <0.001 | ||||||||||||||
全程督导 | 98 | 1.4 | 6710 | 98.6 | 1.00 | ||||||||||
全程管理 | 0 | 0.0 | 24 | 00.0 | 0(0~inf) | 0.993 | |||||||||
强化期督导 | 60 | 0.7 | 8286 | 99.3 | 0.47(0.34~0.65) | <0.001 | |||||||||
自服药 | 3 | 10.0 | 27 | 90.0 | 6.90(2.19~21.78) | <0.001 | |||||||||
系统管理 | 0.001 | ||||||||||||||
否 | 4 | 5.3 | 71 | 94.7 | 1.00 | ||||||||||
是 | 157 | 1.0 | 14976 | 99.0 | 0.19(0.07~0.51) | ||||||||||
白细胞计数 | 0.007 | ||||||||||||||
正常 | 126 | 1.0 | 12892 | 99.0 | 1.00 | ||||||||||
异常 | 35 | 1.6 | 2155 | 98.4 | 1.67(1.15~2.43) | ||||||||||
红细胞计数 | 0.274 | ||||||||||||||
正常 | 117 | 1.1 | 10264 | 98.9 | 1.00 | ||||||||||
异常 | 44 | 0.9 | 4783 | 99.1 | 0.82(0.58~1.17) | ||||||||||
血红蛋白计数 | 0.002 | ||||||||||||||
正常 | 117 | 0.9 | 12346 | 99.1 | 1.00 | ||||||||||
异常 | 44 | 1.6 | 2701 | 98.4 | 1.72(1.21~2.43) | ||||||||||
变量 | 复发 | 未复发 | HR(95%CI)值 | P值 | |||||||||||
例数 | 构成比(%) | 例数 | 构成比(%) | ||||||||||||
血小板计数 | 0.406 | ||||||||||||||
正常 | 148 | 1.0 | 14076 | 99.0 | 1.00 | ||||||||||
异常 | 13 | 1.3 | 971 | 98.7 | 1.27(0.72~2.24) | ||||||||||
中性粒细胞百分比 | 0.728 | ||||||||||||||
正常 | 147 | 1.1 | 13617 | 98.9 | 1.00 | ||||||||||
异常 | 14 | 1.0 | 1430 | 99.0 | 0.91(0.52~1.57) | ||||||||||
淋巴细胞百分比 | 0.021 | ||||||||||||||
正常 | 130 | 1.0 | 13077 | 99.0 | 1.00 | ||||||||||
异常 | 31 | 1.5 | 1970 | 98.5 | 1.58(1.07~2.34) | ||||||||||
单核细胞百分比 | 0.720 | ||||||||||||||
正常 | 114 | 1.0 | 10839 | 99.0 | 1.00 | ||||||||||
异常 | 47 | 1.1 | 4208 | 98.9 | 1.06(0.76~1.49) | ||||||||||
丙氨酸氨基转移酶 | 0.332 | ||||||||||||||
正常 | 143 | 1.1 | 12977 | 98.9 | 1.00 | ||||||||||
异常 | 18 | 0.9 | 2070 | 99.1 | 0.78(048~1.28) | ||||||||||
天冬氨酸氨基转移酶 | 0.001 | ||||||||||||||
正常 | 122 | 0.9 | 12784 | 99.1 | 1.00 | ||||||||||
异常 | 39 | 1.7 | 2263 | 98.3 | 1.81(1.26~2.60) | ||||||||||
总胆红素 | 0.552 | ||||||||||||||
正常 | 148 | 1.0 | 14014 | 99.0 | 1.00 | ||||||||||
异常 | 13 | 1.2 | 1033 | 98.8 | 1.19(0.67~2.09) | ||||||||||
直接胆红素 | 0.043 | ||||||||||||||
正常 | 136 | 1.0 | 13450 | 99.0 | 1.00 | ||||||||||
异常 | 25 | 1.5 | 1597 | 98.5 | 1.55(1.01~2.38) | ||||||||||
间接胆红素 | 0.172 | ||||||||||||||
正常 | 4 | 0.1 | 13048 | 99.9 | 1.00 | ||||||||||
异常 | 2 | 0.1 | 1999 | 99.9 | 3.26(0.60~17.81) | ||||||||||
尿素氮 | <0.001 | ||||||||||||||
正常 | 91 | 0.8 | 11427 | 99.2 | 1.00 | ||||||||||
异常 | 70 | 1.9 | 3620 | 98.1 | 2.43(1.78~3.32) | ||||||||||
空腹血糖 | 0.229 | ||||||||||||||
正常 | 123 | 1.0 | 12061 | 99.0 | 1.00 | ||||||||||
异常 | 38 | 1.3 | 2986 | 98.7 | 1.25(0.87~1.80) | ||||||||||
尿酸 | <0.001 | ||||||||||||||
正常 | 104 | 1.5 | 6885 | 98.5 | 1.00 | ||||||||||
异常 | 57 | 0.7 | 8162 | 99.3 | 0.47(0.34~0.64) | ||||||||||
肌酐 | 0.614 | ||||||||||||||
正常 | 114 | 1.0 | 10904 | 99.0 | 1.00 | ||||||||||
异常 | 47 | 1.1 | 4143 | 98.9 | 1.09(0.78~1.53) |
变量 | β值 | s | Wald χ2值 | aHR(95%CI)值 | P值 |
---|---|---|---|---|---|
性别(以男性为参照) | |||||
女 | -0.37 | 0.200 | 1.840 | 0.69(0.47~1.02) | 0.066 |
本地户籍(以否为参照) | |||||
是 | 0.45 | 0.161 | 2.789 | 1.56(1.14~2.14) | 0.005 |
就诊间隔大于14天(以否为参照) | |||||
是 | -0.58 | 0.170 | 3.416 | 0.56(0.40~0.78) | <0.001 |
诊断时痰检结果(以涂阴为参照) | |||||
涂阳 | 1.07 | 0.168 | 6.379 | 2.92(2.10~4.06) | <0.001 |
治疗2个月末痰检结果(以涂阴为参照) | |||||
涂阳 | 1.37 | 0.252 | 5.439 | 3.94(2.41~6.47) | <0.001 |
其他 | 0.61 | 0.323 | 1.945 | 1.83(1.00~3.39) | 0.052 |
是否合并糖尿病(以否为参照) | |||||
是 | 0.47 | 0.272 | 1.743 | 1.61(0.94~2.73) | 0.081 |
血红蛋白计数(以正常为参照) | |||||
异常 | 1.02 | 0.378 | 2.702 | 2.78(1.32~5.83) | 0.007 |
直接胆红素(以正常为参照) | |||||
异常 | 1.78 | 0.328 | 5.444 | 5.94(3.13~11.79) | <0.001 |
天冬氨酸氨基转移酶(以正常为参照) | |||||
异常 | 0.65 | 0.353 | 1.839 | 1.91(0.96~3.82) | 0.070 |
尿素氮(以正常为参照) | |||||
异常 | 2.17 | 0.286 | 7.579 | 8.76(5.00~15.36) | <0.001 |
尿酸(以正常为参照) | |||||
异常 | -3.66 | 0.321 | 11.390 | 0.03(0.01~0.05) | <0.001 |
[1] | World Health Organization.Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] |
Mirsaeidi M, Sadikot RT. Patients at high risk of tuberculosis recurrence. Int J Mycobacteriol, 2018, 7(1): 1-6. doi: 10.4103/ijmy.ijmy_164_17.
doi: 10.4103/ijmy.ijmy_164_17 pmid: 29516879 |
[3] |
邱玉冰, 许琳, 杨蕊, 等. 云南省成功治疗肺结核患者5年复发情况及影响因素研究. 预防医学, 2020, 32(6):559-562. doi: 10.19485/j.cnki.issn2096-5087.2020.06.005.
doi: 10.19485/j.cnki.issn2096-5087.2020.06.005 |
[4] |
Lee H, Kim J. A study on the relapse rate of tuberculosis and related factors in Korea using nationwide tuberculosis notification data. Osong Public Health Res Perspect, 2014, 5(Suppl): S8-S17. doi: 10.1016/j.phrp.2014.11.001.
doi: 10.1016/j.phrp.2014.11.001 URL |
[5] |
Rosser A, Marx FM, Pareek M. Recurrent tuberculosis in the pre-elimination era. Int J Tuberc Lung Dis, 2018, 22(2): 139-150. doi: 10.5588/ijtld.17.0590.
doi: 10.5588/ijtld.17.0590 pmid: 29506610 |
[6] |
Shen X, Yang C, Wu J, et al. Recurrent tuberculosis in an urban area in China: Relapse or exogenous reinfection? Tuberculosis (Edinb), 2017, 103:97-104. doi: 10.1016/j.tube.2017.01.007.
doi: 10.1016/j.tube.2017.01.007 URL |
[7] |
Bestrashniy JRBM, Nguyen VN, Nguyen TL, et al. Recurrence of tuberculosis among patients following treatment completion in eight provinces of Vietnam: A nested case-control study. Int J Infect Dis, 2018, 74:31-37. doi: 10.1016/j.ijid.2018.06.013.
doi: S1201-9712(18)34448-5 pmid: 29944930 |
[8] |
Velayutham B, Chadha VK, Singla N, et al. Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study. PLoS One, 2018, 13(7): e0200150. doi: 10.1371/journal.pone.0200150.
doi: 10.1371/journal.pone.0200150 URL |
[9] |
邓翔, 蒋在慧, 吕凯. 800例肺结核患者复发情况及相关因素分析. 实用预防医学, 2019, 26(5):611-612,634. doi: 10.3969/j.issn.1006-3110.2019.05.029.
doi: 10.3969/j.issn.1006-3110.2019.05.029 |
[10] | World Health Organization. Definitions and reporting framework for tuberculosis—2013 revision (updated December 2014). Geneva:World Health Organization, 2013. |
[11] |
陈海平, 陈丽峰, 陆锁兴, 等. 2005—2020年全国法定传染病发病情况分析. 中国城乡企业卫生, 2021, 36(8): 111-115. doi: 10.16286/j.1003-5052.2021.08.042.
doi: 10.16286/j.1003-5052.2021.08.042 |
[12] |
张屹立, 郑晓宇, 吴悦. 某市2008—2017年结核患者复发因素调查研究. 中国医药指南, 2021, 19(11):121-122. doi: 10.15912/j.cnki.gocm.2021.11.055.
doi: 10.15912/j.cnki.gocm.2021.11.055 |
[13] |
戴志松, 陈堃, 林淑芳, 等. 福建省成功治疗的肺结核患者10年复发情况及影响因素分析. 疾病监测, 2021, 36(11):1152-1158. doi: 10.3784/jbjc.202106300378.
doi: 10.3784/jbjc.202106300378 |
[14] |
魏建华, 郭涛, 王昱. 2型糖尿病合并初治菌阳肺结核临床治愈后复发率及影响因素分析. 宁夏医学杂志, 2018, 40(9):819-820. doi: 10.13621/j.1001-5949.018.09.0819.
doi: 10.13621/j.1001-5949.018.09.0819 |
[15] |
Segafredo G, Kapur A, Robbiati C, et al. Integrating TB and non-communicable diseases services: Pilot experience of screening for diabetes and hypertension in patients with Tuberculosis in Luanda, Angola. PLoS One, 2019, 14(7):e0218052. doi: 10.1371/journal.pone.0218052.
doi: 10.1371/journal.pone.0218052 URL |
[16] |
张灿有, 陈彬, 叶建君, 等. 中国重点人群肺结核患病与发病调查分析. 中国防痨杂志, 2021, 43(12): 1260-1268. doi: 10.3969/j.issn.1000-6621.2021.12.006.
doi: 10.3969/j.issn.1000-6621.2021.12.006 |
[17] |
Moosazadeh M, Bahrampour A, Nasehi M, et al. The incidence of recurrence of tuberculosis and its related factors in smear-positive pulmonary tuberculosis patients in Iran: A retrospective cohort study. Lung India, 2015, 32(6):557-560. doi: 10.4103/0970-2113.168113.
doi: 10.4103/0970-2113.168113 pmid: 26664159 |
[18] |
地尔木拉提·吐孙, 麦维兰江·阿不力米提, 刘振江, 等. 2011—2020年新疆喀什地区初治肺结核患者复发影响因素分析. 中国防痨杂志, 2021, 43(11):1176-1182. doi: 10.3969/j.issn.1000-6621.2021.11.013.
doi: 10.3969/j.issn.1000-6621.2021.11.013 |
[19] |
张懿行, 王伟炳, 李小攀, 等. 454例不规则治疗肺结核患者复发的相关因素分析. 上海预防医学, 2019, 31(12):1015-1019. doi: 10.19428/j.cnki.sjpm.2019.18842.
doi: 10.19428/j.cnki.sjpm.2019.18842 |
[20] |
郑明娟, 谢威. 健康体检人群不同尿酸水平及发生高尿酸血症的相关因素研究. 贵州医药, 2021, 45(12):1981-1982. doi: 10.3969/j.issn.1000-744X.2021.12.081.
doi: 10.3969/j.issn.1000-744X.2021.12.081 |
[21] |
汤永翔, 白卢皙, 杨烈, 等. 某市交通警察高尿酸血症患病情况及相关危险因素分析. 职业卫生与应急救援, 2017, 35(2):99-102. doi: 10.16369/j.oher.issn.1007-1326.2017.02.001.
doi: 10.16369/j.oher.issn.1007-1326.2017.02.001 |
[1] | XIA Hui, ZHENG Yang, SONG Yuan-yuan. Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645. |
[2] | LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653. |
[3] | LU Ni-hong, SHEN Ling-jun, LIU Hong-lu, CHEN Yang-jun, YANG Yan, DU Ying-rong. Clinical value of ESAT-6, immune and inflammatory indexes in the diagnosis of anti-tuberculosis drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 654-659. |
[4] | YU Chun-hong, LIU Xing, SHEN Ling-jun, LI Hai-wen, LI Xie, WU Rong-shuang, LI Xian-rui, FAN Hao. Meta analysis of efficacy and safety of the treatment containing bedaquiline for multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 660-668. |
[5] | DAI Xiao-wei, WANG Nen-han, CHEN Shuang-shuang, YANG Xin-yu, TIAN Li-li, CHEN Hong, ZHANG Hong-tai, LI Chuan-you. Assessing next-generation sequencing for Mycobacterium tuberculosis diagnosis in clinical sputum samples [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 669-679. |
[6] | RAO Hai-tao, DONG Wei-jie, QIN Shi-bing. The clinical features of 653 cases of thoracic spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 675-680. |
[7] | KANG Wan-li, LI Tian-jing, WANG Sai-sai, LI Chang-hua, ZHAO Qiu-yue, ZHENG Su-hua, LIU Yang. Study on the trend and prediction of reported incidence of national active pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 681-684. |
[8] | CHEN Yan-mei, WEN Wen-pei, WU Hui-zhong, XU Liu-yue, PENG Ke-hao, YU Mei-ling. Analysis of monitoring results of tuberculosis drug-resistance in Guangdong Province from 2016 to 2020 [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 685-689. |
[9] | GAO Li, PANG Xue-wen, ZHANG Guo-qin, LI Jing-xin, ZHANG Fan. Analysis of risk factors for recurrence within 2 years after successful treatment of newly treated active pulmonary tuberculosis in Tianjin [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 698-703. |
[10] | XUE Xiao, ZHANG Dong-yan, AI Ping, DENG Ling, CHEN Wei, HU Yuan-lian, JIA Xue-jiao, YANG Guo-liang, XIN Zhen-jiang, CHANG Li-jie. Analysis of the usage of electronic pillbox and WeChat App in pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 704-710. |
[11] | PANG Yu, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, LIU Yu-hong. Analysis of the application of tuberculosis telemedicine consultation and training platform based on internet technology [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 711-715. |
[12] | NIE Wen-juan, ZHOU Wen-qiang, CHU Nai-hui. Research progress on pharmacokinetics and drug interaction of bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 716-719. |
[13] | JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping. Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726. |
[14] | YANG Chi, WANG Zhen-wei, SHA Wei. Advances in research on treatments of multidrug-resistant tuberculosis with Chinese traditional medicine [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 727-731. |
[15] | TIAN Na, CHU Hong-qian, SUN Zhao-gang. Recent progress of Nano-drug delivery system for tuberculosis treatment [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 732-737. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||